OVB Stock Overview
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ovoca Bio plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0083 |
| 52 Week High | €0.15 |
| 52 Week Low | €0.0045 |
| Beta | 0.68 |
| 1 Month Change | 17.86% |
| 3 Month Change | -8.33% |
| 1 Year Change | -86.25% |
| 3 Year Change | -92.83% |
| 5 Year Change | -87.31% |
| Change since IPO | -98.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| OVB | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 13.8% | 8.3% | 2.2% |
| 1Y | -86.3% | 4.9% | 0.9% |
Return vs Industry: OVB underperformed the UK Pharmaceuticals industry which returned 0.2% over the past year.
Return vs Market: OVB underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| OVB volatility | |
|---|---|
| OVB Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: OVB's share price has been volatile over the past 3 months.
Volatility Over Time: OVB's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 5 | Kirill Golovanov | ovocabio.com |
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018.
Ovoca Bio plc Fundamentals Summary
| OVB fundamental statistics | |
|---|---|
| Market cap | UK£419.52k |
| Earnings (TTM) | -UK£2.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs OVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OVB income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €2.33m |
| Earnings | -€2.33m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OVB perform over the long term?
See historical performance and comparison